Home › Squamous Cell Carcinoma ng Ulo at Leeg › Florida › Orlando
Pag-aaral pangklinika para sa Squamous Cell Carcinoma ng Ulo at Leeg sa Orlando, FL
16 pag-aaral para sa Squamous Cell Carcinoma ng Ulo at Leeg ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Orlando (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Nagre-recruitPhase 1
- Exelixis Clinical Site #48, Celebration · 17 mi ang layo
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Nagre-recruitPhase 3
- AdventHealth Medical Group Oncology and Hematology at Orlando, Orlando
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Nagre-recruitPhase 3
- AdventHealth Orlando, Orlando
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Nagre-recruitPhase 1
- Sara Cannon Research Institute Lake Nona, Orlando
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Nagre-recruitPhase 1/2
- Florida Cancer Specialists - Lake Nona, Orlando
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Nagre-recruitPhase 2
- Orlando Health, Orlando
SMP-3124LP in Adults With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Advent Health, Celebration · 17 mi ang layo
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Nagre-recruitPhase 1/2
- Clermont Oncology Center, Clermont · 24 mi ang layo
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institute (Lake Nona), Orlando
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Nagre-recruitPhase 1
- Florida Cancer Specialists - Lake Nona, Orlando
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Nagre-recruitPhase 1
- Florida Cancer Specialists, Orlando
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Nagre-recruitPhase 3
- AdventHealth Medical Group Oncology & Hematology at Orlando, Orlando
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- Florida Cancer Specialists-Lake Nona, Orlando
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Nagre-recruitPhase 1
- Dren Investigational Site, Orlando
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- Research Site 137, Orlando
- Research Site 118, Celebration · 17 mi ang layo
Pag-aaral para sa Squamous Cell Carcinoma ng Ulo at Leeg sa ibang lungsod
- Houston, TX47 pag-aaral
- Los Angeles, CA42 pag-aaral
- Boston, MA40 pag-aaral
- New York City, NY39 pag-aaral
- Nashville, TN39 pag-aaral
- St. Louis, MO28 pag-aaral
- Arlington, VA26 pag-aaral
- Philadelphia, PA26 pag-aaral
- Chicago, IL26 pag-aaral
- Atlanta, GA24 pag-aaral
- San Antonio, TX22 pag-aaral
- New Haven, CT22 pag-aaral
Iba pang pag-aaral sa Orlando
- Non-Small Cell Lung Cancer44 pag-aaral
- Obesity32 pag-aaral
- Metastatic Cancer29 pag-aaral
- Overweight27 pag-aaral
- Sakit ni Alzheimer25 pag-aaral
- Type 2 Diabetes25 pag-aaral
- Kanser (lahat ng uri)24 pag-aaral
- Kanser sa Suso23 pag-aaral
- Kanser sa Ovary22 pag-aaral
- Ulcerative Colitis22 pag-aaral
- Kanser sa Baga21 pag-aaral
- Colorectal Cancer19 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.